Johnson & Johnson plans to establish four regional innovation centers in major life sciences hubs around the world as part of an effort to accelerate early innovation and enhance collaboration and investment opportunities.
The centers will be located in California, Boston, London and China, and will serve as regional hubs focused on identifying early-stage innovations, and establishing collaborations to speed drug development. The innovation centers will provide scientists, entrepreneurs and emerging companies focused on early-stage opportunities with access J&J experts, who can facilitate collaborations across its pharmaceutical, medical device and diagnostics and consumer companies.
“As a leading healthcare company, our goal is to have continuous access to the best science and technology in the world,” said Dr. Paul Stoffels, worldwide chairman, pharmaceuticals, Johnson & Johnson. “The innovation centers allow us to be closer to where the innovation occurs, to access and invest in the best early-stage science and technology, and to fuel our business as well as the health of the innovation ecosystem overall. Together with innovators and entrepreneurs, we can more rapidly deliver value and make a difference in the health and lives of people worldwide.”